

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/P97A69D9447EN.html>

Date: March 2020

Pages: 62

Price: US\$ 2,000.00 (Single User License)

ID: P97A69D9447EN

Abstracts

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2020, provides an overview of the Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline landscape.

Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. Proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision and difficulty with color perception.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press

releases.

The Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 2 and 2 respectively.

Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Proliferative Diabetic Retinopathy (PDR) - Overview
- Proliferative Diabetic Retinopathy (PDR) - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Proliferative Diabetic Retinopathy (PDR) - Therapeutics Assessment
 - Assessment by Target
 - Assessment by Mechanism of Action
 - Assessment by Route of Administration
 - Assessment by Molecule Type
- Proliferative Diabetic Retinopathy (PDR) - Companies Involved in Therapeutics Development
 - Acucela Inc
 - Aerie Pharmaceuticals Inc
 - Antisense Therapeutics Ltd
 - Generium
 - Kuur Therapeutics Ltd
 - NeuBase Therapeutics Inc
 - Oxurion NV
 - Protheragen Inc
- Proliferative Diabetic Retinopathy (PDR) - Drug Profiles
 - AR-13503 SR - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - atesidorsen sodium - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - brolocizumab - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - emixustat hydrochloride - Drug Profile
 - Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit SCG3 for Metabolic Disorders, Oncology and
Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

squalamine lactate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THR-687 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proliferative Diabetic Retinopathy (PDR) - Dormant Projects

Proliferative Diabetic Retinopathy (PDR) - Product Development Milestones

Featured News & Press Releases

May 08, 2016: Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic
Retinopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Proliferative Diabetic Retinopathy (PDR) - Pipeline by Acucela Inc, H1 2020

Proliferative Diabetic Retinopathy (PDR) - Pipeline by Aerie Pharmaceuticals Inc, H1 2020

Proliferative Diabetic Retinopathy (PDR) - Pipeline by Antisense Therapeutics Ltd, H1 2020

Proliferative Diabetic Retinopathy (PDR) - Pipeline by Generium, H1 2020

Proliferative Diabetic Retinopathy (PDR) - Pipeline by Kuur Therapeutics Ltd, H1 2020

Proliferative Diabetic Retinopathy (PDR) - Pipeline by NeuBase Therapeutics Inc, H1 2020

Proliferative Diabetic Retinopathy (PDR) - Pipeline by Oxurion NV, H1 2020

Proliferative Diabetic Retinopathy (PDR) - Pipeline by Protheragen Inc, H1 2020

Proliferative Diabetic Retinopathy (PDR) - Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Acucela Inc

Aerie Pharmaceuticals Inc

Antisense Therapeutics Ltd

Generium

Kuur Therapeutics Ltd

NeuBase Therapeutics Inc

Oxurion NV

Protheragen Inc

I would like to order

Product name: Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/P97A69D9447EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P97A69D9447EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970